4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Urothelial cancer is the second most common cancer, and cause of cancer death, related to the genitourinary tract. The goals of surveillance imaging after the treatment of urothelial cancer of the urinary bladder are to detect new or previously undetected urothelial tumors, to identify metastatic disease, and to evaluate for complications of therapy. For surveillance, patients can be stratified into one of three groups: (1) nonmuscle invasive bladder cancer with no symptoms or additional risk factors; (2) nonmuscle invasive bladder cancer with symptoms or additional risk factors; and (3) muscle invasive bladder cancer. This article is a review of the current literature for urothelial cancer and resulting recommendations for surveillance imaging. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

          Related collections

          Author and article information

          Journal
          J Am Coll Radiol
          Journal of the American College of Radiology : JACR
          Elsevier BV
          1558-349X
          1546-1440
          Nov 2019
          : 16
          : 11S
          Affiliations
          [1 ] Panel Vice-Chair, Duke University Medical Center, Durham, North Carolina. Electronic address: brian.allen@duke.edu.
          [2 ] Panel Chair, University of Chicago, Chicago, Illinois.
          [3 ] Memorial Sloan Kettering Cancer Center, New York, New York.
          [4 ] Mayo Clinic, Jacksonville, Florida.
          [5 ] McGill University, Montreal, Quebec, Canada.
          [6 ] Mayo Clinic, Rochester, Minnesota.
          [7 ] Urology Clinics of North Texas, Dallas, Texas, American Urological Association.
          [8 ] Huntsman Cancer Hospital, Salt Lake City, Utah.
          [9 ] UPMC, Pittsburgh, Pennsylvania, American Urological Association.
          [10 ] Cleveland Clinic, Cleveland, Ohio.
          [11 ] Stanford University Medical Center, Stanford, California.
          [12 ] Ottawa Hospital Research Institute and the Department of Radiology, The University of Ottawa, Ottawa, Ontario, Canada.
          [13 ] National Institutes of Health, Bethesda, Maryland.
          [14 ] University of Pennsylvania, Philadelphia, Pennsylvania.
          [15 ] The University of Texas MD Anderson Cancer Center, Houston, Texas.
          [16 ] University of Washington, Seattle Cancer Care Alliance, Seattle, Washington.
          [17 ] Rhode Island Hospital/The Warren Alpert Medical School of Brown University, Providence, Rhode Island.
          [18 ] Specialty Chair, University of Alabama at Birmingham, Birmingham, Alabama.
          Article
          S1546-1440(19)30616-7
          10.1016/j.jacr.2019.05.026
          31685109
          4e88bed7-629c-4474-a165-c9de5f1cc685
          Copyright © 2019 American College of Radiology. Published by Elsevier Inc. All rights reserved.
          History

          Appropriate Use Criteria,Urothelial cancer,Transitional cell carcinoma,Surveillance,Nonmuscle invasive bladder cancer,Muscle invasive bladder cancer,Bladder cancer,Appropriateness Criteria,AUC

          Comments

          Comment on this article